New bladder cancer therapy to start clinical trials

June 27, 2017, Cancer Research UK
New bladder cancer therapy to start clinical trials
Credit: Cancer Research UK

An experimental treatment for bladder cancer will move into an early phase clinical trial under an agreement signed today (Monday) between Cancer Research UK and Cancer Research Technology (CRT), the charity's commercial arm, and Canadian biotechnology company Sitka Biopharma Inc ., a spin-off of The Centre for Drug Research and Development (CDRD) and the University of British Columbia (UBC), financed by Quark Venture .

The new treatment called STK-01 is being developed to improve delivery of chemotherapy for non-muscle invasive (NMIBC), in patients whose tumour has not yet penetrated into the muscle layer of the .

Standard treatment for NMIBC involves removal of the tumour followed by intravesical therapies (delivered by catheter directly into the bladder) to eliminate residual disease and prevent recurrence and progression. STK-01 uses a unique nanoparticle polymer technology to deliver the chemotherapy docetaxel.

Docetaxel is an effective chemotherapy drug but it can be difficult to deliver enough of the drug to the bladder to treat the cancer. STK-01 may overcome this resulting in the tumour being exposed to much higher levels of the drug. In preclinical studies STK-01 has been shown to greatly enhance docetaxel penetration and retention in the bladder wall, and is extremely effective at eliminating tumours in mouse models.

Under the agreement, Cancer Research UK and Sitka will share the cost of the development and production of STK-01 for the clinic.

Cancer Research UK's Centre for Drug Development (CDD) will then fund and manage a Phase I clinical trial of STK-01 in bladder cancer patients, to evaluate drug safety, toxicity, drug delivery and how it compares with giving docetaxel alone.

The trial will take place across the Experimental Cancer Medicine Centres (ECMC) network, a nationwide initiative funded by Cancer Research UK and the UK's four Health Departments.

Dr Michael Parr, Sitka Biopharma's President and Chief Scientific Officer, said: "This agreement is very significant for Sitka as it will validate our preclinical therapy and take another step closer to providing an effective treatment for bladder cancer patients. Working with Cancer Research UK, CRT and CDD – world leaders in the development of cancer treatments – has helped us reach a significant value-creation point for Sitka, taking it from a pre-clinical to clinical stage company. Results of this work will be applied to new therapeutic technologies in development for other forms of cancer, such as ovarian cancer, and provide effective treatments for even more patients."

Dr Nigel Blackburn, Cancer Research UK's director of , said: "More than 5,000 people die from each year in the UK and we urgently need to find new and better ways to treat patients. We hope this experimental approach will improve survival for patients with invasive disease by increasing the amount of chemotherapy that can reach the tumour.

"Without our innovative CDP scheme it might have been years before this reached patients so we're pleased to work with Sitka Biopharma to accelerate development of this promising technology."

Explore further: Drug created from malaria parasite shows promise as bladder cancer treatment

Related Stories

Drug created from malaria parasite shows promise as bladder cancer treatment

April 20, 2017
A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.

Blood test provides clues to bladder cancer patients' prognoses

February 13, 2017
New research indicates that about one-quarter of patients with bladder cancer treated with radical surgery on curative intent have detectable levels of tumour cells circulating in their blood. The presence of circulating ...

Simple post-surgery step significantly reduces bladder cancer recurrence

May 15, 2017
It's just one step. Flushing the bladder with a common chemotherapy drug after a cancerous tumor is surgically removed reduces the chances of that cancer returning. Canadian and European clinical trials have proven this true ...

FDA OKs immune-boosting drug for advanced bladder cancer

May 1, 2017
U.S. regulators have approved a new drug that harnesses the immune system to treat advanced bladder cancer.

Clinical trial could lead to new bladder cancer drug

November 24, 2015
A bladder cancer drug tested in a University of Hawai'i Cancer Center clinical trial is getting closer to Food and Drug Administration (FDA) approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined ...

Combined modality treatment could be first course for muscle-invasive bladder cancer

May 31, 2017
A meta-analysis of previously published cancer research showed no difference in five-year and 10-year survival rates between patients who underwent radical cystectomy, which is the surgical removal of the bladder, and a bladder-preserving ...

Recommended for you

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.